LTRN Overview

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Wall Street analysts forecast LTRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTRN is25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lantern Pharma Inc revenue for the last quarter amounts to -3.40M USD, decreased -28.67

Lantern Pharma Inc. EPS for the last quarter amounts to -3772627.00 USD, decreased -13.80

Lantern Pharma Inc (LTRN) has 16 emplpoyees as of June 19 2026.

Today LTRN has the market capitalization of 48.36M USD.